Has Mark Walker received payments from drug or device companies?

Yes. Drug and device makers reported $24,025 in general payments to Mark Walker across 180 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Walker did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Walker come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Walker

Internal Medicine · Albuquerque, NMNPI 1407876907

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,218 of the $24,025 with a category attached, or 63.3%. Novo Nordisk accounts for 70.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $13,876 and has fallen 95.4% since, to $641 in 2021. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,025in general payments, 2019–2025

Across 180 payments — averaging $133.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$17K
AstraZeneca$6K
Lilly USA, LLC$562
Boehringer Ingelheim$506
Pfizer$149
Johnson & Johnson$101
plus $205 from 7 others

$2,895in research payments, 2019–2025

Across 2 payments — averaging $1447.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$3K

What the payments were for

Consulting fees$4,73720%
Speaking & faculty fees$15,21863%
Travel & lodging$7053%
Food & beverage$3,33414%
Education$320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	62	$16,839
AstraZeneca	37	$5,663
Lilly USA, LLC	32	$562
Boehringer Ingelheim	15	$506
Pfizer	14	$149
Johnson & Johnson	5	$101
Teva Pharmaceuticals USA, Inc.	5	$70
Novartis	3	$39
E.r. Squibb & Sons, L.L.C.	2	$26
Merck	2	$25
Eli Lilly	1	$18
Tactile Systems Technology Inc	1	$15
Amarin Pharma, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Saxenda$11,518
FARXIGA$4,849
Victoza$4,393
JARDIANCE$266
Tresiba$132

How this compares

$24,025 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico →

Other internal medicine in Albuquerque

Edward LewieckiAlbuquerque$491K
James AdairAlbuquerque$108K
Gulshan ParasherAlbuquerque$66K
Joao TeixeiraAlbuquerque$18K
Karla AlmarazAlbuquerque$18K
David SosaAlbuquerque$11K
Revati ReddyAlbuquerque$7K
Ross DavidsonAlbuquerque$7K
Edmee RodriguezAlbuquerque$6K
Anthony ChuangAlbuquerque$5K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →